Spyre Therapeutics, Inc. Income Statement
SYRE / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 12 fiscal years. All figures from audited SEC 10-K filings.
Spyre Therapeutics, Inc. reported $0 in revenue and $155M in net loss for FY2025. Revenue has declined at a 21.0% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886.0K | $0 | $18.7M | $3.9M | $5.2M | $4.6M | $5.2M | $4.6M | - | - |
| SG&A Expense | $47.9M | $45.8M | $39.9M | $21.8M | $27.3M | $12.6M | $10.1M | $8.4M | $10.1M | $8.4M | $5.9M | $2.1M |
| R&D Expense | $171.7M | $162.8M | $89.5M | $59.6M | $57.1M | $36.7M | $22.8M | $18.1M | $22.8M | $18.1M | $11.5M | $6.8M |
| Operating Income | -$209.6M | -$208.6M | -$242.3M | -$81.5M | -$65.6M | -$45.5M | -$27.7M | -$21.9M | -$27.7M | -$21.9M | -$11.3M | -$8.9M |
| Income Tax | -$15.0K | $51.0K | -$26.0K | $0 | $141.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$155.2M | -$208.0M | -$338.8M | -$80.9M | -$65.8M | -$44.3M | -$27.2M | -$21.7M | -$27.2M | -$21.7M | -$11.3M | -$10.3M |
| EPS (Basic) | - | - | -$25.02 | -$1.52 | - | - | - | - | - | - | - | - |
| EPS (Diluted) | - | - | -$25.02 | -$1.52 | -$2.45 | -$2.13 | -$1.80 | -$2.22 | - | - | - | - |
| Shares Outstanding | 60.3M | 36.1M | 2.6M | 49.4M | 48.0M | 29.1M | 24.1M | 16.7M | 15.1M | 9.8M | 599.8K | - |
| Operating Margin | - | - | -27348.0% | - | -350.3% | -1169.3% | -531.7% | -473.3% | - | - | - | - |
| Profit Margin | - | - | -38238.2% | - | -351.1% | -1140.6% | -523.3% | -468.8% | - | - | - | - |